Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | CONTACT-303: primary PFS analysis of atezolizumab and cabozantinib in ccRCC

Toni Choueiri, MD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of the results from the Phase III CONTACT-303 (NCT04338269) study which aimed to investigate the efficacy and safety of atezolizumab plus cabozantinib after progression with prior immune-checkpoint inhibitor (ICI) treatment in clear-cell renal-cell carcinoma (ccRCC). The results revealed that combinatory intervention resulted in no difference in progression-free survival (PFS), overall survival (OS), or response rate (RR) and was associated with increased toxicity in patients with ccRCC exposed to prior ICIs. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.